Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study

Fig. 2

Dynamic changes in inflammatory markers during tocilizumab use in TA patients. A Dynamic changes in C3, C4, and CH50 in the 12 months of follow-up. B Dynamic changes in ESR, CRP, and IL-6 in the 12 months of follow-up. *Compared with baseline (0 month); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. C3, complement 3; C4, complement 4; CH50, 50% hemolytic complement; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IL-6, interleukin-6

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us